“Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s669. doi:10.25251/2vrcdb23.